Proteomics

Dataset Information

0

Proteomic analysis of secretory granules in dopaminergic neurons of Parkinson`s disease

ABSTRACT: Parkinson disease (PD) is the second most common age-related neurodegenerative disorder, which is related to neurotransmitter secretion impartment and the dysfunction of vesicle transport. Secretory granules (SGs) are a class of intracellular vesicles different from synaptic vesicles (SVs) in neurons and the neuroendocrine cells. They represent the primary subcellular site for the biosynthesis, storage and releasing of the neuropeptides, neurotransmitters and hormones. In the current study, we characterized the proteome of secretory granules in dopaminergic neurons in PD. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis was used to identify proteins in SGs. A total of 4249 proteins were identified in the SGs in normal and MPP+-treated SH-Sy5Y dopaminergic neurons in total. This study regarded the biological alternations of SGs in PD as an entry point. By studying the significantly differentially expressed proteins, it is helpful to better understand the molecular mechanisms of SGs disorders in the pathology of PD, and provide a basis for vesicle transport theory in pathogenesis of PD.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Xiaoni ZHan  

LAB HEAD: Xiaoni Zhan

PROVIDER: PXD023937 | Pride | 2021-08-26

REPOSITORIES: Pride

Json Xml
altmetric image

Publications

Proteomic characterization of secretory granules in dopaminergic neurons indicates chromogranin/secretogranin-mediated protein processing impairment in Parkinson's disease.

Wen Gehua G   Pang Hao H   Wu Xu X   Jiang Enzhu E   Zhang Xique X   Zhan Xiaoni X  

Aging 20210821 16

Parkinson's disease (PD) is an aging disorder related to vesicle transport dysfunctions and neurotransmitter secretion. Secretory granules (SGs) are large dense-core vesicles for the biosynthesis of neuropeptides and hormones. At present, the involvement of SGs impairment in PD remains unclear. In the current study, we found that the number of SGs in tyrosine hydroxylase-positive neurons and the marker proteins secretogranin III (Scg3) significantly decreased in the substantia nigra and striatum  ...[more]

Similar Datasets

Proteomics,Multiomics platelet hyperreactivity project
2016-02-22 | PXD001861 | Pride
Metabolomics Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease
2020-12-21 | MTBLS2266 | MetaboLights
Transcriptomics RNA-Seq profiling of dopaminergic neurons from iPSCs of Parkinson's disease patients
2016-06-07 | E-MTAB-4586 | biostudies-arrayexpress
Transcriptomics Expression data from fibroblasts, iPSCs and neurons with four copies of SNCA, and equivalent cell lines from an unaffected first degree relative
2011-09-14 | E-GEOD-28365 | biostudies-arrayexpress
Transcriptomics The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson’s disease
2021-10-06 | GSE152768 | GEO
Transcriptomics A primate nigrostriatal atlas of neuronal vulnerability and resilience in a model of Parkinson’s disease
2023-11-19 | E-MTAB-13437 | biostudies-arrayexpress
Transcriptomics Phenotypic differences in dopaminergic circuitries of mouse strains are associated with extensive regulatory variation in the midbrain
2019-10-07 | E-MTAB-8333 | biostudies-arrayexpress
Other Base editing of Ptbp1 in neurons alleviates symptoms in a Parkinson’s disease mouse model
2024-04-02 | GSE237570 | GEO
Transcriptomics Direct reprogramming of human fibroblasts to expandable induced dopaminergic neuronal progenitors for Parkinson’s disease therapy [Array]
2023-08-31 | GSE157392 | GEO
Genomics Direct reprogramming of human fibroblasts to expandable induced dopaminergic neuronal progenitors for Parkinson’s disease therapy [ChIP-seq]
2023-08-31 | GSE157340 | GEO